lobbying_activities: 1817061
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1817061 | 9563d79e-4cad-42a2-9d3c-9d7d2c24f6df | Q1 | COVINGTON & BURLING LLP | 11195 | FABRE-KRAMER PHARMACEUTICALS, INC | 2016 | first_quarter | PHA | Policy regarding demonstration of effectiveness for new drug approvals. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2016-04-19T16:06:40.910000-04:00 |